|
1
|
She J, Yang P, Hong Q and Bai C: Lung
cancer in China: Challenges and interventions. Chest.
143:1117–1126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weir HK, Thun MJ, Hankey BF, Ries LA, Howe
HL, Wingo PA, Jemal A, Ward E, Anderson RN and Edwards BK: Annual
report to the nation on the status of cancer, 1975–2000, featuring
the uses of surveillance data for cancer prevention and control. J
Natl Cancer Inst. 95:1276–1299. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shimamura T, Li D, Ji H, Haringsma HJ,
Liniker E, Borgman CL, Lowell AM, Minami Y, McNamara K, Perera SA,
et al: Hsp90 inhibition suppresses mutant EGFR-T790M signaling and
overcomes kinase inhibitor resistance. Cancer Res. 68:5827–5838.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang H, Chen D, Cui QC, Yuan X and Dou QP:
Celastrol, a triterpene extracted from the Chinese ‘Thunder of God
Vine’ is a potent proteasome inhibitor and suppresses human
prostate cancer growth in nude mice. Cancer Res. 66:4758–4765.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sukpondma Y, Rukachaisirikul V and
Phongpaichit S: Antibacterial caged-tetraprenylated xanthones from
the fruits of Garcinia hanburyi. Chem Pharm Bull (Tokyo).
53:850–852. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu ZQ, Guo QL, You QD, Zhao L and Gu HY:
Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1
cells in vivo and in vitro and represses telomerase activity
and telomerase reverse transcriptase mRNA expression in the cells.
Biol Pharm Bull. 27:1769–1774. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guo QL, Lin SS, You QD, Gu HY, Yu J, Zhao
L, Qi Q, Liang F, Tan Z and Wang X: Inhibition of human telomerase
reverse transcriptase gene expression by gambogic acid in human
hepatoma SMMC-7721 cells. Life Sci. 78:1238–1245. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao L, Guo QL, You QD, Wu ZQ and Gu HY:
Gambogic acid induces apoptosis and regulates expressions of Bax
and Bcl-2 protein in human gastric carcinoma MGC-803 cells. Bio
Pharm Bull. 27:998–1003. 2004. View Article : Google Scholar
|
|
9
|
Yi T, Yi Z, Cho SG, Luo J, Pandey MK,
Aggarwal BB and Liu M: Gambogic acid inhibits angiogenesis and
prostate tumor growth by suppressing vascular endothelial growth
factor receptor 2 signaling. Cancer Res. 68:1843–1850. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sano T, Takeuchi S, Nakagawa T, Ishikawa
D, Nanjo S, Yamada T, Nakamura T, Matsumoto K and Yano S: The novel
phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor,
BEZ235, circumvents erlotinib resistance of epidermal growth factor
receptor mutant lung cancer cells triggered by hepatocyte growth
factor. Int J Cancer. 133:505–513. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li D, Ambrogio L, Shimamura T, Kubo S,
Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A,
Himmelsbach F, et al: BIBW2992, an irreversible EGFR/HER2 inhibitor
highly effective in preclinical lung cancer models. Oncogene.
27:4702–4711. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wong KK, Fracasso PM, Bukowski RM, Lynch
TJ, Munster PN, Shapiro GI, Jänne PA, Eder JP, Naughton MJ, Ellis
MJ, et al: A phase I study with neratinib (HKI-272), an
irreversible pan ErbB receptor tyrosine kinase inhibitor, in
patients with solid tumors. Clin Cancer Res. 15:2552–2558. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao Q, Yang Y, Yu J, You QD, Zeng S, Gu
HY, Lu N, Qi Q, Liu W, Wang XT, et al: Posttranscriptional
regulation of the telomerase hTERT by gambogic acid in human
gastric carcinoma 823 cells. Cancer Lett. 262:223–231. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pandey MK, Sung B, Ahn KS, Kunnumakkara
AB, Chaturvedi MM and Aggarwal BB: Gambogic acid, a novel ligand
for transferrin receptor, potentiates TNF-induced apoptosis through
modulation of the nuclear factor-kappaB signaling pathway. Blood.
110:3517–3525. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Adrain C, Creagh EM and Martin SJ: Defying
death: Showing Bcl-2 the way home. Nat Cell Biol. 5:9–11. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu J, Zhou M, Ouyang J, Wang J, Zhang Q,
Xu Y, Xu Y, Zhang Q, Xu X and Zeng H: Gambogic acid induces
mitochondria-dependent apoptosis by modulation of Bcl-2 and Bax in
mantle cell lymphoma JeKo-1 cells. Chin J Cancer Res. 25:183–191.
2013.PubMed/NCBI
|
